Inflammatix Secures $57 Million to Advance Novel Diagnostic for Patients with Suspected Infections or Sepsis

Posted on by

Fundraise brings lead product, TriVerity™ Test, closer to commercialization following recent submission to FDA SUNNYVALE, Calif., Sept. 12, 2024 /PRNewswire/ — Inflammatix, a pioneering molecular diagnostics company, announced today the closing of $57 million in Series E financing, led…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.